KORRO BIO INC (KRRO)
Health Care · Oligonucleotide therapeutics / genetic disease treatment · NASDAQ
Clinical-stage oligonucleotide therapeutics company developing investigational GalNAc-conjugated therapies for genetic and protein misfolding diseases.
What KORRO BIO INC does
Korro Bio, Inc. is a biopharmaceutical company that researches, develops, and aims to commercialize oligonucleotide-based therapeutics using GalNAc-conjugation technology. The company focuses on treating genetic diseases and protein misfolding disorders through its lead development program, KRRO-121 for alpha-1 antitrypsin deficiency (AATD), with plans to submit a regulatory application in the second half of 2026. Korro Bio operates through a combination of Legacy Korro Bio Ops, Inc. (acquired via business combination in November 2023) and its predecessor Frequency Therapeutics, employing oligonucleotide research and next-generation therapeutic approaches to address serious unmet medical needs.
Themes: ["Oligonucleotide therapeutics","Genetic diseases / rare genetic disorders","Alpha-1 antitrypsin deficiency (AATD)","GalNAc-conjugation technology","Protein misfolding disorders"]
Fundamentals
- Price$14.30 as of 2026-07-09 close
- Market cap$205M as of 2026-07-10
- 1-year return+8.4% as of 2026-07-09 close
- Net margin-1834.5% as of 2026-07-10
- Gross margin+44.7% as of 2026-07-10
- ROE-117.9% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Revenue growth (YoY)-20.3% as of 2026-07-10
- Beta3.03 as of 2026-07-10
Key risks (from latest filing)
["Clinical development risk: Success of KRRO-121 regulatory application submission and approval depends on achieving favorable clinical trial results; any failure in the Phase 2 or Phase 3 programs could materially impact the company's pipeline and valuation.","Collaboration uncertainty: Paused Novo Nordisk collaboration and dependency on securing future partnerships or licensing arrangements to fund operations and advance development programs.","Cash runway and operating losses: Significant unprofitability (negative net margin of -1834.48%) and cash consumption create substantial risk that the company may not have sufficient funds to reach meaningful clinical milestones or commercialization without additional financing."]
Competitors & peers
- Ionis Pharmaceuticals (IONS)
- Antisense Pharma (or similar antisense/oligonucleotide developers)
- Alnylam Pharmaceuticals (ALNY)
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.